These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 17908630

  • 1. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma.
    Sureda A.
    Hematol Oncol Clin North Am; 2007 Oct; 21(5):943-60. PubMed ID: 17908630
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Stem cell transplantation for pediatric lymphoma: past, present and future.
    Bradley MB, Cairo MS.
    Bone Marrow Transplant; 2008 Jan; 41(2):149-58. PubMed ID: 18084337
    [Abstract] [Full Text] [Related]

  • 4. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
    Nademanee A, Forman SJ.
    Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
    [Abstract] [Full Text] [Related]

  • 5. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma.
    Claviez A, Sureda A, Schmitz N.
    Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S16-24. PubMed ID: 18978738
    [Abstract] [Full Text] [Related]

  • 6. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
    Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL, Hahn T.
    Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
    [Abstract] [Full Text] [Related]

  • 7. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
    Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M, Banna G, Tirelli U, Soligo D, Santoro A.
    Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967
    [Abstract] [Full Text] [Related]

  • 8. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
    Laport GF, Williams SF.
    Semin Oncol; 1998 Aug; 25(4):503-17. PubMed ID: 9728600
    [Abstract] [Full Text] [Related]

  • 9. Therapy of relapsed Hodgkin lymphoma.
    Cashen AF, Bartlett NL.
    Blood Rev; 2007 Sep; 21(5):233-43. PubMed ID: 17683834
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reduced intensity allogeneic stem cell transplantation for low grade non-Hodgkin's lymphoma.
    Morris EC, Mackinnon S.
    Best Pract Res Clin Haematol; 2005 Mar; 18(1):129-42. PubMed ID: 15694189
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
    Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ.
    Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
    [Abstract] [Full Text] [Related]

  • 14. Salvage therapy in Hodgkin's lymphoma.
    Byrne BJ, Gockerman JP.
    Oncologist; 2007 Feb; 12(2):156-67. PubMed ID: 17296811
    [Abstract] [Full Text] [Related]

  • 15. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
    Glossmann JP, Staak JO, Nogova L, Diehl V, Scheid C, Kisro J, Reis HE, Peter N, Engert A, Josting A.
    Ann Hematol; 2005 Aug; 84(8):517-25. PubMed ID: 15759115
    [Abstract] [Full Text] [Related]

  • 16. High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma.
    Laurence AD, Goldstone AH.
    Semin Hematol; 1999 Jul; 36(3):303-12. PubMed ID: 10462330
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group.
    Morschhauser F, Brice P, Fermé C, Diviné M, Salles G, Bouabdallah R, Sebban C, Voillat L, Casasnovas O, Stamatoullas A, Bouabdallah K, André M, Jais JP, Cazals-Hatem D, Gisselbrecht C, GELA/SFGM Study Group.
    J Clin Oncol; 2008 Dec 20; 26(36):5980-7. PubMed ID: 19018090
    [Abstract] [Full Text] [Related]

  • 20. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease.
    Tey S, Butler J, Durrant S, Hill G, Morton J, Kennedy G.
    Bone Marrow Transplant; 2005 Sep 20; 36(6):553-4; author reply 554. PubMed ID: 16044146
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.